Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.

Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol. 2009 Sep 20; 27(27):4487-91.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Boronic Acids
Bortezomib
Carcinoma, Non-Small-Cell Lung
Cetuximab
Female
Health Status
Humans
Lung Neoplasms
Male
Middle Aged
Pyrazines
Taxoids

authors with profiles

Everett E. Vokes